Intrinsic dissolution simulation of highly and poorly soluble drugs for BCS solubility classification by Duque, Marcelo Dutra et al.
6 NOVEMBER 2017
INTRODUCTION
Intrinsic dissolution is a characterization test for active pharmaceutical ingredients (APIs) where the dissolution rate of a drug is determined from a specific surface 
area exposed to a dissolution medium at certain rotation 
speed. (1, 2) The intrinsic dissolution rate (IDR) can be 
used to estimate the solubility class of a substance 
according to the Biopharmaceutics Classification System 
(BCS) guidelines. (3, 4) It can be also valuable to evaluate 
differences between polymorphs and solvates. (2)
According to the BCS, drugs are classified as high or low 
solubility. (5) Equilibrium solubility testing (shake flask 
method) is recommended by the US Food and Drug 
Administration to determine the solubility of drugs, 
allowing to obtain their BCS class. (6–10) However, this 
method requires the saturation of aqueous solutions, 
which can be a challenge depending on the drug 
characteristics, mainly in the early stages of development. 
For this purpose, intrinsic dissolution is an important 
characterization test that can be used to obtain the 
solubility of drugs according to BCS guidelines. (3, 4)
The dissolution of an API in a formulation is affected by 
different factors such as the test conditions (temperature, 
rotation speed, pH, nature of dissolution medium) and 
formulation factors, such as compaction pressure and 
excipient interactions. (1) Using design of experiments 
(DOE) is one way to evaluate the most appropriate test 
conditions. (11, 12)
Although only a few milligrams of API is used in intrinsic 
dissolution testing, developing a method requires a 
reasonable number of experiments to evaluate the 
impact of the test conditions on the IDR. One of the 
strategies to reduce the number of experiments is using 
fractional factorial design to develop appropriate intrinsic 
dissolution methods. (11, 12) However, depending on 
the quantity of the available sample, this step can be 
unfeasible, in early stages of the development process, 
where only limited material is available. Approaches, 
which can further reduce experimental testing, are highly 
desirable.
DDDPlus™ (Dose Disintegration and Dissolution) version 
4.0, designed by Simulations Plus Inc., is a computer 
program used to simulate in vitro dissolution tests 
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employing USP apparatuses 1 (basket), 2 (paddle), and 
4 (flow-through cell) and intrinsic dissolution using the 
rotating disk method. (13) The use of DDDPlus to simulate 
in vitro dissolution from tablets containing low soluble 
drugs, montelukast sodium and glyburide, was previously 
demonstrated. (14) This software can simulate intrinsic 
dissolution tests, saving time, reducing the number of 
experiments to investigate suitable IDR conditions.
The objective of this work was to demonstrate the use 
of the computer program DDDPlus as a tool for BCS 
solubility classification by simulating intrinsic dissolution 
tests for the poorly soluble drug, pyrimethamine, and the 
highly soluble drug, metronidazole.
MATERIALS AND METHODS
Materials
Pyrimethamine and metronidazole were kindly donated by 
Farmanguinhos Laboratory/Fiocruz (Rio de Janeiro, Brazil) 
and Micro Service Micronização e Processos (Diadema, 
Brazil), respectively. Both APIs were of pharmaceutical 
grade and were used as received. Hydrochloric acid (HCl) 
P.A. 37%, glacial acetic acid, sodium acetate, potassium 
phosphate monobasic monohydrate, potassium chloride, 
and sodium hydroxide were purchased from Labsynth 
Products Laboratories (Diadema, Brazil) and used to 
prepare the buffer solutions as described below.
Hydrochloric acid pH 1.2 was prepared by accurately 
pipetting 7 mL of HCl P.A. 37% and weighing 3.73 g of 
potassium chloride per liter. Hydrochloric acid 0.1 M was 
prepared by pipetting 8.3 mL of HCl P.A. 37% and adding 
purified water to 1 L.
Acetate buffer pH 4.5 was prepared by dissolving 2.99 g 
of sodium acetate, 14 mL 2-N acetic acid solution, and 
purified water. Phosphate buffer pH 7.2 was prepared 
by dissolving 6.8 g of potassium phosphate monobasic 
monohydrate and 1.4 g of NaOH, and adding purified 
water. The amounts of material were used to prepare 1 L 
of buffer solutions.
Intrinsic dissolution tests
For pyrimethamine, intrinsic dissolution testing was 
performed according to a fractional factorial design 
33-1 using Statistica® 12.0 (StatSoft, Inc., Tulsa, OK, USA) 
including factors such as compaction pressure (1.75, 3.5, 
and 7.0 kN), nature of the dissolution medium (HCl pH 1.2; 
acetate buffer pH 4.5, and phosphate buffer pH 7.2), and 
rotation speed (50, 100, and 200 rpm), generating the 
experiments described in Table 1.
Table 1. Pyrimethamine Intrinsic Dissolution Test Conditions
Standard 
order
Run 
order
Compaction 
pressure 
(kN)
Dissolution media
Rotation 
speed (rpm)
1 P1 1.75 HCl pH 1.2 50
2 P4 1.75
Acetate buffer pH 
4.5
200
3 P7 1.75
Phosphate buffer 
pH 7.2
100
4 P2 3.5 HCl pH 1.2 200
5 P5 3.5
Acetate buffer pH 
4.5
100
6 P8 3.5
Phosphate buffer 
pH 7.2
50
7 P3 7.0 HCl pH 1.2 100
8 P6 7.0
Acetate buffer pH 
4.5
50
9 P9 7.0
Phosphate buffer 
pH 7.2
200
HCl, hydrochloric acid.
Rotating disk apparatuses from Varian Inc. (Palo Alto, CA, 
USA) coupled to a D-800 Logan dissolution tester (Logan 
Instruments Corp., NJ, USA) was used to perform the 
intrinsic dissolution tests. About 150 mg of the drug was 
weighed in triplicate and compacted using a hydraulic 
press (American Lab., São Paulo, Brazil). The temperature 
used was 37 ± 0.5°C; the volume of the dissolution 
medium was 900 mL, and aliquots of 5 mL were collected 
in intervals until a sufficient number of points were 
obtained.
Each aliquot of dissolution medium was immediately 
replaced at the same volume and temperature. 
The amount of drug dissolved was analyzed by a 
spectrophotometric method in a UV-VIS Cary 50 (Varian 
Inc.) using quartz cuvettes of 10.0 mm at 273 nm, using 
each dissolution media as blank.
The visual evaluation of the compacted drug’s surface was 
monitored during the experiments to avoid erroneous 
data from possible alterations, which can be detected by 
the presence of curvatures in the plots and low values of 
linearity. All dissolution media were previously degassed 
to prevent bubble formation, which could hamper the 
dissolution of the drug. (1, 3)
Intrinsic dissolution rate was calculated according to 
United States Pharmacopeia (1). The amount of drug 
dissolved (mg) was plotted versus time (s), and through 
linear regression, R2 and the corresponding equation was 
obtained. The slope of this equation is the dissolution 
rate, and this value was divided by the exposed surface 
area (0.5 cm2) to obtain the IDR (mg/s/cm2).
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For metronidazole, the results from an earlier study (11) 
were used for the simulations. The authors conducted 
the experiments according to a 34-1 fractional factorial 
design, resulting in 27 experiments, including factors 
such as compaction pressure, rotation speed, dissolution 
media, and metronidazole micronization degree. The 
study confirmed that API micronization did not influence 
IDR results. (11)
Therefore, in this work, we considered only compaction 
pressure, rotation speed, and dissolution media as 
parameters, since there is no influence by particle size on 
IDR. Furthermore, DDDPlus disables the use of particle 
size distribution of the drug when intrinsic dissolution is 
selected. It resulted in a 33-1 fractional factorial design 
(Table 2), from which corresponding in vitro IDR values 
were used for comparison.
Table 2. Metronidazole Intrinsic Dissolution Test Conditions
Standard 
order
Run 
order
Compaction 
pressure 
(kN)
Dissolution media
Rotation 
speed (rpm)
1 M1 3.5 HCl 0.1 M 50
2 M8 3.5 Purified water 100
3 M6 3.5
Phosphate buffer 
pH 7.2
75
4 M16 7.0 HCl 0.1 M 100
5 M14 7.0 Purified water 75
6 M12 7.0
Phosphate buffer 
pH 7.2
50
7 M22 10.5 HCl 0.1 M 75
8 M20 10.5 Purified water 50
9 M27 10.5
Phosphate buffer 
pH 7.2
100
HCl, hydrochloric acid.
Computer simulations using DDDPlus
DDDPlus software was used to simulate the intrinsic 
dissolution tests. A database for pyrimethamine and one 
for metronidazole were created in the software.
The ADMET Predictor™ module present in the computer 
program, GastroPlus™ (Simulations Plus Inc.) can 
accurately predict absorption, metabolism, elimination, 
and toxicity characteristics of substances from its 
molecular structure. This module was used to estimate 
solubility vs pH data for each drug at 25°C. For this 
purpose, files containing the molecular structure of each 
drug were used in this module, and the following solubility 
data were obtained: pyrimethamine solubility = 0.03 mg/
mL at pH 8.37 and metronidazole solubility = 13.42 mg/
mL at pH 7.66. Although the estimated solubility was at 
25°C, these values were used as input data in DDDPlus 
because they are in accordance to shake-flask results 
experiments conducted at 37°C in our lab: pyrimethamine 
solubility = 0.04 mg/mL at phosphate buffer 0.05 M 
pH 7.5 and metronidazole solubility = 13.14 mg/mL at 
phosphate buffer 0.05 M pH 7.2. The pKa values of 7.4 
(pyrimethamine) and 2.55 (metronidazole) were obtained 
from the literature (15, 16); particle density (1.2 g/mL), 
precipitation time (900 s), and diffusion coefficient (0.5 
cm2/s × 10-5) were used as default values from DDDPlus.
Intrinsic dissolution tests conditions for both 
pyrimethamine (Table 1) and metronidazole (Table 2) 
were used as input data into the Experimental tab of the 
software. Single simulations were performed for each 
experiment. As described in the pyrimethamine intrinsic 
dissolution tests section, IDR was calculated from the 
simulated data for both drugs. The values from simulated 
intrinsic dissolution tests were compared to the in vitro 
results.
Statistical analysis
Observed IDR values for pyrimethamine and 
metronidazole were analyzed using Statistica 12.0. 
Analysis of Variance (ANOVA) was used with p < 0.05 to 
establish statistical significant differences; Pareto charts 
where generated for each API.
RESULTS
Intrinsic dissolution and computer simulations
For pyrimethamine, the amount of drug dissolved was 
plotted against time to obtain a slope to calculate the IDR. 
A simulated amount of pyrimethamine dissolved versus 
time from DDDPlus was used to predict IDR.
Observed and predicted IDR values for pyrimethamine 
and the regression coefficients are shown in Table 3.
Similarly, for metronidazole the simulated amounts 
dissolved versus time were used to predict the IDR, and in 
vitro IDR data were used to compare to the predicted IDR 
with the observed IDR (Table 4).
For both drugs, Pareto charts showed that only dissolution 
media presented a significant influence on IDR (Figures 
1 and 2), which was also confirmed by ANOVA of IDR 
observed results with significant influence for the variable 
dissolution medium (p = 0.021 for pyrimethamine and p = 
0.011 for metronidazole).
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Table 3. In Vitro (Observed) and In Silico (Predicted) Intrinsic Dissolution 
Rate (IDR) and R2 Values for Pyrimethamine
Experiment
Dissolution 
media
IDR (mg/s/cm2)
Observed 
vs Predicted 
IDR
Observed Predicted R2
P1 HCl pH 1.2 0.0028 0.0030 0.9956
P2 HCl pH 1.2 0.0052 0.0050 0.9987
P3 HCl pH 1.2 0.0046 0.0046 0.9919
P4
Acetate buffer 
pH 4.5
0.0068 0.0072 0.9976
P5
Acetate buffer 
pH 4.5
0.0072 0.0070 0.9865
P6
Acetate buffer 
pH 4.5
0.0080 0.0072 0.9860
P7
Phosphate 
buffer pH 7.2
0.00008 0.00008 0.9762
P8
Phosphate 
buffer pH 7.2
0.00016 0.00016 0.9881
P9
Phosphate 
buffer pH 7.2
0.00008 0.00012 0.9424
Table 4. In Vitro (Observed) and In Silico (Predicted) Intrinsic Dissolution 
Rate (IDR) and R2 Values for Metronidazole
Experiment
Dissolution 
media
IDR (mg/s/cm2)
Observed 
vs Predicted 
IDR
Observed Predicted R2
M1 HCl 0.1 M 0.0752 0.0752 0.9994
M8 Purified water 0.0294 0.0298 0.9997
M6
Phosphate 
buffer pH 7.2
0.0231 0.0236 0.9996
M16 HCl 0.1 M 0.1072 0.1082 0.9996
M14 Purified water 0.0256 0.0254 0.9992
M12
Phosphate 
buffer pH 7.2
0.0195 0.0198 0.9974
M22 HCl 0.1 M 0.0874 0.0878 0.9993
M20 Purified water 0.0204 0.0214 0.9970
M27
Phosphate 
buffer pH 7.2
0.0254 0.0262 0.9998
DISCUSSION
Solubility is one of the most relevant API physicochemical 
characteristics evaluated in preformulation studies 
because it is related to drug dissolution and presumably 
to in vivo performance of the drug product. (17) In early 
stages of drug discovery, solubility can be evaluated using 
small amounts of API via intrinsic dissolution testing. (3)
Pyrimethamine is a weak base with pKa 7.4 (15) expected 
to be ionized at acid pH. This drug had higher observed 
IDR values for the experiments conducted at pH 4.5 (P4, 
P5 and P6), followed by pH 1.2 (P1, P2 and P3) and lower 
values for the experiments P7, P8 and P9, conducted 
at pH 7.2 (Table 3). Metronidazole is also a weak basic 
compound and is more soluble at pH values below 2 (18), 
which was confirmed by the higher observed IDR values 
when intrinsic dissolution was performed using HCl 0.1 
M as dissolution medium (M1, M16, and M22). Lower 
observed IDR values for this drug were observed for the 
experiments at higher pH test conditions (Table 4).
The determination of IDR from APIs can be used to 
evaluate and classify the API’s solubility according to BCS 
guidelines when the dose is not too high or very low. (19) 
Intrinsic dissolution test results show that IDR represents 
the pH-dependent solubility of pyrimethamine and 
metronidazole, confirming IDR’s suitability to determine 
the solubility classification of both low and highly soluble 
drugs. The use of intrinsic dissolution tests to determine 
the solubility of drugs according to BCS has been reported 
in the literature. (3, 4)
For intrinsic dissolution testing, the conditions of surface 
area, temperature, rotation speed, pH, and ionic strength 
must be kept constant, as described in Equation 1. 
(13, 20)
         (Equation 1),
where
     Mu = amount of undissolved drug
     γ = calibration constant (unitless)
     A= surface area of the tablet (cm2)
     D= diffusion coefficient (cm2/min)
     ω = rotational rate of the disk apparatus (radians/sec)
     μ = dynamic viscosity (g cm-1s-1)
     Cs= saturation solubility (mg/mL)
According to Equation 1, IDR increases as the rotation 
speed is improved, but the statistical analysis for 
experimental conditions used (independent factors and 
respective levels) showed that, for pyrimethamine (low 
soluble drug), the influence of rotation speed was only 
observed in the experiments conducted using HCl pH 1.2 
(Table 3). For metronidazole, this influence could be noted 
within the results of the same medium (Table 4), but 
when comparing to the others, different rotation speeds 
can lead to similar IDR values. Thus, dissolution medium 
was the variable that showed significant influence on IDR 
for pyrimethamine (Figure 1) and metronidazole (Figure 
2), with p < 0.05.
=-0.62γAD
dMu
dt
ω
2 3 1 2
-1 6μ Cs
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Due to its higher solubility at pH 4.5, acetate buffer could 
be chosen as a suitable dissolution medium for intrinsic 
dissolution tests for pyrimethamine. For metronidazole, 
although the dissolution medium influenced IDR, all 
studied media are suitable, due to the high solubility. Any 
of the tested compaction pressures and rotation speeds 
for both drugs can be used for the intrinsic dissolution 
tests, because they did not have a significant effect on IDR; 
however, it is recommended to fix one set of conditions to 
compare samples of these drugs from different suppliers.
The simulations obtained in this work showed a high 
correlation between observed and predicted IDR values 
for pyrimethamine (Table 3) and metronidazole (Table 4), 
showing that DDDPlus can be used to estimate the intrinsic 
dissolution of both, low and highly soluble drugs. The IDR 
values found for both drugs showed a pH-dependency on 
their solubility.
DDDPlus was able to predict the intrinsic dissolution values 
that were used to calculate IDR for each test condition, 
showing its accuracy in estimating differences in solubility 
as the pH changed. IDR values above 0.0017 mg/s/cm2 
indicate a highly soluble drug. (3, 19) Pyrimethamine 
did not show IDR results higher than this value for all pH 
tested; therefore, it can be considered a low soluble drug. 
Metronidazole presented IDR values above 0.0017 mg/s/
cm2, confirming its high solubility. These findings correlate 
with the BCS classification of the drugs: pyrimethamine – 
class II or IV and metronidazole – class I. (21)
Metronidazole’s degree of micronization was used as 
additional factor by a previous study (11), which confirmed 
that particle size does not impact IDR. DDDPlus does not 
use particle size distribution when intrinsic dissolution is 
selected for simulation, thus micronization differences 
between metronidazole samples were not considered in 
simulations. The software was able to simulate IDR values 
for metronidazole with a high correlation R2 ≥ 0.9970 
(Table 4) with the in vitro data for different intrinsic 
dissolution test conditions.
DDDPlus can accurately predict IDR for the studied drugs, 
showing that this software can be used to estimate 
drug’s solubility according to BCS classification and the 
best conditions for intrinsic dissolution tests, reducing 
the number of laboratory experiments, and helping 
pharmaceutical companies to save time and costs.
CONCLUSION
Computer simulations using DDDPlus can help to gain 
biopharmaceutical understanding of APIs in the drug 
development process. Software simulations can be 
used to predict the intrinsic dissolution of API’s in the 
physiologically relevant pH range of 1 to 7.2. This can 
help streamline and minimize experimental lab work. 
Key experiments can be identified by the simulations and 
be confirmed by lab results to characterize important 
biopharmaceutical API properties.
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Figure 1. Pareto chart for the effects of variables: dissolution media,
compaction pressure, and rotation speed on intrinsic dissolution rate
(IDR) for pyrimethamine.
Figure 2. Pareto chart for the effects of variables: dissolution media,
compaction pressure, and rotation speed on intrinsic dissolution rate
(IDR) for metronidazole.
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